EconPapers    
Economics at your fingertips  
 

Details about Nancy Devlin

E-mail:
Homepage:https://www.linkedin.com/in/nancy-devlin-595b1b18
Phone:++64 204219622
Postal address:PO Box 694 Wānaka 9343 New Zealand
Workplace:Centre for Health Policy, University of Melbourne, (more information at EDIRC)
Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield, (more information at EDIRC)
Office of Health Economics, (more information at EDIRC)

Access statistics for papers by Nancy Devlin.

Last updated 2022-11-06. Update your information in the RePEc Author Service.

Short-id: pde347


Jump to Journal Articles

Working Papers

2016

  1. “New Age” Decision Making in HTA: Is It Applicable in Asia?
    Briefing, Office of Health Economics Downloads

2013

  1. Methods for the estimation of the NICE cost effectiveness threshold
    Working Papers, Centre for Health Economics, University of York Downloads View citations (49)
  2. The influence of cost-effectiveness and other factors on NICE decisions
    Working Papers, Centre for Health Economics, University of York Downloads View citations (8)
    See also Journal Article The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions, Health Economics, John Wiley & Sons, Ltd. (2015) Downloads View citations (21) (2015)

2012

  1. Analysing Hospital Variation in Health Outcome at the Level of EQ-5D Dimensions
    Working Papers, Centre for Health Economics, University of York Downloads View citations (1)
  2. Time to tweak the TTO. But how?
    MPRA Paper, University Library of Munich, Germany Downloads View citations (1)

2011

  1. Truly inefficient or providing better quality of care? Analysing the relationship between riskadjusted hospital costs and patients’ health outcomes
    Working Papers, Centre for Health Economics, University of York Downloads View citations (5)
    See also Journal Article TRULY INEFFICIENT OR PROVIDING BETTER QUALITY OF CARE? ANALYSING THE RELATIONSHIP BETWEEN RISK‐ADJUSTED HOSPITAL COSTS AND PATIENTS' HEALTH OUTCOMES, Health Economics, John Wiley & Sons, Ltd. (2013) Downloads View citations (17) (2013)

2000

  1. Allocating Vote: Health — ‘Needs Assessment’ and an Economics-Based Approach
    Treasury Working Paper Series, New Zealand Treasury Downloads
  2. The health state preferences and logistical inconsistencies of New Zealanders: a tale of two tariffs
    Working Papers, Centre for Health Economics, University of York Downloads View citations (6)

Journal Articles

2022

  1. A Comparison of PROPr and EQ-5D-5L Value Sets
    PharmacoEconomics, 2022, 40, (3), 297-307 Downloads View citations (1)
  2. Correction to: Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures
    PharmacoEconomics, 2022, 40, (4), 477-478 Downloads View citations (1)
  3. How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents
    PharmacoEconomics, 2022, 40, (2), 157-182 Downloads
  4. Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review
    PharmacoEconomics, 2022, 40, (7), 663-698 Downloads
  5. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
    Applied Health Economics and Health Policy, 2022, 20, (5), 651-667 Downloads
  6. Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures
    PharmacoEconomics, 2022, 40, (4), 379-431 Downloads View citations (1)

2021

  1. Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
    Applied Health Economics and Health Policy, 2021, 19, (5), 635-644 Downloads View citations (2)
  2. EQ-5D-5L Health-State Values for the Mexican Population
    Applied Health Economics and Health Policy, 2021, 19, (6), 905-914 Downloads View citations (1)
  3. Giving a Voice to Marginalised Groups for Health Care Decision Making
    The Patient: Patient-Centered Outcomes Research, 2021, 14, (1), 5-10 Downloads
  4. Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia
    Health Economics, 2021, 30, (8), 1950-1977 Downloads View citations (1)
  5. Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
    Medical Decision Making, 2021, 41, (5), 584-596 Downloads
  6. What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the development of the EQ-HWB?
    The European Journal of Health Economics, 2021, 22, (7), 1067-1081 Downloads View citations (2)

2020

  1. A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’
    Social Science & Medicine, 2020, 246, (C) Downloads View citations (5)
  2. An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values
    The European Journal of Health Economics, 2020, 21, (7), 1091-1103 Downloads View citations (4)
  3. Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland
    Health Policy, 2020, 124, (6), 639-646 Downloads View citations (1)
  4. International Valuation Protocol for the EQ-5D-Y-3L
    PharmacoEconomics, 2020, 38, (7), 653-663 Downloads View citations (2)
  5. Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?
    PharmacoEconomics, 2020, 38, (4), 325-340 Downloads View citations (7)
  6. The impact of price transparency on consumers and providers: A scoping review
    Health Policy, 2020, 124, (8), 819-825 Downloads View citations (5)

2019

  1. A new method for valuing health: directly eliciting personal utility functions
    The European Journal of Health Economics, 2019, 20, (2), 257-270 Downloads View citations (7)
  2. All Male Panels and Other Diversity Considerations for ISPOR
    PharmacoEconomics - Open, 2019, 3, (3), 423-426 Downloads
  3. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments
    The European Journal of Health Economics, 2019, 20, (1), 99-105 Downloads View citations (1)

2018

  1. 3L, 5L, What the L? A NICE Conundrum
    PharmacoEconomics, 2018, 36, (6), 637-640 Downloads View citations (2)
  2. Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
    PharmacoEconomics - Open, 2018, 2, (2), 153-163 Downloads View citations (1)
  3. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
    PharmacoEconomics, 2018, 36, (6), 699-713 Downloads View citations (7)
  4. Correction to: 3L, 5L, What the L? A NICE Conundrum
    PharmacoEconomics, 2018, 36, (6), 729-729 Downloads View citations (2)
  5. Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
    PharmacoEconomics, 2018, 36, (6), 727-727 Downloads View citations (1)
  6. New methods for modelling EQ‐5D‐5L value sets: An application to English data
    Health Economics, 2018, 27, (1), 23-38 Downloads View citations (11)
  7. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L
    PharmacoEconomics, 2018, 36, (11), 1345-1353 Downloads View citations (6)
  8. Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment
    The European Journal of Health Economics, 2018, 19, (4), 595-605 Downloads View citations (3)
  9. Valuing health‐related quality of life: An EQ‐5D‐5L value set for England
    Health Economics, 2018, 27, (1), 7-22 Downloads View citations (31)

2017

  1. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
    Applied Health Economics and Health Policy, 2017, 15, (4), 469-477 Downloads View citations (4)
  2. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial
    The Patient: Patient-Centered Outcomes Research, 2017, 10, (6), 677-686 Downloads
  3. EQ-5D and the EuroQol Group: Past, Present and Future
    Applied Health Economics and Health Policy, 2017, 15, (2), 127-137 Downloads View citations (39)
  4. Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale
    The European Journal of Health Economics, 2017, 18, (8), 967-977 Downloads View citations (2)

2016

  1. What Determines the Shape of an EQ-5D Index Distribution?
    Medical Decision Making, 2016, 36, (8), 941-951 Downloads View citations (2)

2015

  1. A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)
    PharmacoEconomics, 2015, 33, (8), 867-877 Downloads View citations (6)
  2. INTER‐PROVIDER COMPARISON OF PATIENT‐REPORTED OUTCOMES: DEVELOPING AN ADJUSTMENT TO ACCOUNT FOR DIFFERENCES IN PATIENT CASE MIX
    Health Economics, 2015, 24, (1), 41-54 Downloads View citations (2)
  3. Local health care expenditure plans and their opportunity costs
    Health Policy, 2015, 119, (9), 1237-1244 Downloads View citations (6)
  4. The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions
    Health Economics, 2015, 24, (10), 1256-1271 Downloads View citations (21)
    See also Working Paper The influence of cost-effectiveness and other factors on NICE decisions, Working Papers (2013) Downloads View citations (8) (2013)

2013

  1. A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO
    Health Economics, 2013, 22, (5), 517-532 Downloads View citations (23)
  2. Hospital Variation in Patient-Reported Outcomes at the Level of EQ-5D Dimensions
    Medical Decision Making, 2013, 33, (6), 804-818 Downloads View citations (8)
  3. Lead versus lag-time trade-off variants: does it make any difference?
    The European Journal of Health Economics, 2013, 14, (1), 25-31 Downloads View citations (2)
  4. One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands
    The European Journal of Health Economics, 2013, 14, (1), 65-73 Downloads View citations (5)
  5. Operationalizing Value-Based Pricing of Medicines
    PharmacoEconomics, 2013, 31, (1), 1-10 Downloads View citations (13)
  6. TRULY INEFFICIENT OR PROVIDING BETTER QUALITY OF CARE? ANALYSING THE RELATIONSHIP BETWEEN RISK‐ADJUSTED HOSPITAL COSTS AND PATIENTS' HEALTH OUTCOMES
    Health Economics, 2013, 22, (8), 931-947 Downloads View citations (17)
    See also Working Paper Truly inefficient or providing better quality of care? Analysing the relationship between riskadjusted hospital costs and patients’ health outcomes, Working Papers (2011) Downloads View citations (5) (2011)
  7. The development of new research methods for the valuation of EQ-5D-5L
    The European Journal of Health Economics, 2013, 14, (1), 1-3 Downloads View citations (11)
  8. The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework
    The European Journal of Health Economics, 2013, 14, (1), 15-24 Downloads View citations (3)
  9. Time to tweak the TTO: results from a comparison of alternative specifications of the TTO
    The European Journal of Health Economics, 2013, 14, (1), 43-51 Downloads View citations (3)

2011

  1. A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach
    Health Economics, 2011, 20, (3), 348-361 Downloads View citations (35)

2010

  1. An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions
    PharmacoEconomics, 2010, 28, (11), 987-993 Downloads View citations (2)
  2. Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data
    Health Economics, 2010, 19, (8), 886-905 Downloads View citations (11)
  3. Protocols for Time Tradeoff Valuations of Health States Worse than Dead: A Literature Review
    Medical Decision Making, 2010, 30, (5), 610-619 Downloads View citations (14)
  4. Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?
    Medical Decision Making, 2010, 30, (5), 556-565 Downloads View citations (7)

2009

  1. A note on the nature of utility in time and health and implications for cost utility analysis
    Social Science & Medicine, 2009, 68, (2), 362-367 Downloads View citations (8)
  2. Identifying the impact of government targets on waiting times in the NHS
    Health Care Management Science, 2009, 12, (1), 1-10 Downloads View citations (32)
  3. Searching for cost effectiveness thresholds in the NHS
    Health Policy, 2009, 91, (3), 239-245 Downloads View citations (29)

2007

  1. ‘Is there a case for using visual analogue scale valuations in CUA? Yes there is a case, but what does it add to ordinal data?’ a rejoinder
    Health Economics, 2007, 16, (6), 649-651 Downloads

2006

  1. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making
    Health Policy, 2006, 77, (3), 352-367 Downloads View citations (10)
  2. A theoretical framework for TTO valuations of health
    Health Economics, 2006, 15, (10), 1149-1154 Downloads View citations (9)
  3. Is there a case for using visual analogue scale valuations in cost‐utility analysis?
    Health Economics, 2006, 15, (7), 653-664 Downloads View citations (32)

2005

  1. A ‘new and improved’ EQ-5D valuation questionnaire?
    The European Journal of Health Economics, 2005, 6, (1), 73-82 Downloads View citations (3)
  2. Continuity through change: The rhetoric and reality of health reform in New Zealand
    Social Science & Medicine, 2005, 61, (2), 253-262 Downloads View citations (9)

2004

  1. Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis
    Health Economics, 2004, 13, (5), 437-452 Downloads View citations (116)
  2. Getting Health Economics into Practice, Edited by David Kernick. Radcliffe Medical Press, Oxford, 2002. No. of pages: 358. ISBN 1‐85775‐575‐8
    Health Economics, 2004, 13, (5), 499-500 Downloads

2003

  1. Logical inconsistencies in survey respondents' health state valuations ‐ a methodological challenge for estimating social tariffs
    Health Economics, 2003, 12, (7), 529-544 Downloads View citations (24)

2002

  1. The Purchasing of Health Care by Primary Care Organisations. An evaluation and Guide to Future Policy, by N. Mays, S. Wyke, G. Malbon, N. Goodwin. Open University Press, Buckingham and Philadelphia, 2001. No. of pages: 320. ISBN 0‐335‐20900‐9
    Health Economics, 2002, 11, (6), 567-568 Downloads

2001

  1. Health care spending and economic output: Granger causality
    Applied Economics Letters, 2001, 8, (8), 561-564 Downloads View citations (56)

1999

  1. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule
    Social Science & Medicine, 1999, 49, (6), 763-779 Downloads View citations (3)

1996

  1. The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand
    Health Policy, 1996, 38, (2), 101-115 Downloads View citations (8)

1995

  1. Comment: Financing New Zealand’s Tertiary Education: How Much Subsidy?
    Agenda - A Journal of Policy Analysis and Reform, 1995, 2, (2), 223-225 Downloads

1994

  1. The effects of denturism: New Zealand dentists' response to competition
    American Journal of Public Health, 1994, 84, (10), 1675-1677
 
Page updated 2024-04-18